title: Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
authors.affiliation: Université Paris 6, AP-HP, Service de Dermatologie-Allergologie, Hôpital Tenon, France.
authors.forename: Feriel
authors.initials: F
authors.lastname: Fennira
authors.affiliation: Université Paris 6, AP-HP, Service de Dermatologie-Allergologie, Hôpital Tenon, France.
authors.forename: François
authors.initials: F
authors.lastname: Chasset
authors.affiliation: Université de Clermont-Ferrand, Service de Rhumatologie, Hôpital G-Montpied, France.
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
authors.affiliation: Unité de Dermatologie et Médicine Interne, CHU de Pointe à Pitre, Université des Antilles, Guadeloupe.
authors.forename: Nadège
authors.initials: N
authors.lastname: Cordel
authors.affiliation: Université Paris VII, APHP, Service de Dermatologie, Hôpital Saint Louis, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Petit
authors.affiliation: Université Paris 6, AP-HP, Service de Dermatologie-Allergologie, Hôpital Tenon, France. Electronic address: camille.frances@tnn.aphp.fr.
authors.forename: Camille
authors.initials: C
authors.lastname: Francès
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D000077269:Lenalidomide; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide